Recombinant peptide and protein biosimilars, built for global supply.
Our innovator-aligned microbial platforms deliver the purity, scale, and regulatory confidence global pharmaceutical partners need.
HOW WE BUILD BIOSIMILARS
Proprietary platforms, built to advance high-barrier recombinant biosimilars

01
Proprietary Platforms
- Proprietary microbial expression systems, led by YESTIDE™
- Yeast-based platform engineered for recombinant peptide and protein biosimilars
- Spanning GLP-1, insulin, and immunology
01
Proprietary Platforms
- Proprietary microbial expression systems, led by YESTIDE™
- Yeast-based platform engineered for recombinant peptide and protein biosimilars
- Spanning GLP-1, insulin, and immunology
02
Manufacturing Systems
- Advanced fermentation and downstream systems, led by CONTINEX™
- Continuous manufacturing platform for process consistency and scalable output
- Designed for dependable long-term supply
03
From Platform to Pipeline
- Active biosimilar programs with confirmed FTO in key global markets
- Structured pathways for licensing and supply
- Platform science delivered as commercializable programs
A focused pipeline of high-value recombinant biosimilars.
Our growing portfolio of recombinant biosimilar programs across GLP-1, insulin, and immunology spans various stages of development with confirmed FTO in key global markets and structured pathways for licensing and supply.
Manufacturing capabilities

Pre-Seed Bioreactor (100L) x2

Seed Bioreactor (1000L) x4

Production Bioreactor (10000L) x5

Continuous Centrifuge

Downstream Purification

Preparative Chromatography
R&D Capabilities

Sequence & Construct Engineering

Multi-Host Expression Platforms

Strain / Clone Development

Cell Banking & Stability Systems

Media & Seed Train Optimization

Scalable Fermentation Development
Analytical Capabilities

UHPLC

HPLC-UV/PDA

LC–MS

HRMS

SEC-HPLC

qPCR












